However, some pathways, such as those related to immune depletion or the promotion of tumor growth, were significantly up-regulated in patients with CTNNB1-MUT, perhaps explaining why HCC patients with CTNNB1-MUT have a significantly worse immunotherapy prognosis. Here, CTNNB1 is linked to hepatocellular carcinoma.